Compare Incyte Corporation (INCY) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Vanguard International High Dividend Yield ETF — how do they compare? Incyte Corporation trades at $113.05 (market cap $22.85B), while Vanguard International High Dividend Yield ETF trades at $100.53 (market cap $22.80B). The key difference: Incyte Corporation and Vanguard International High Dividend Yield ETF are close in size by market cap, and Vanguard International High Dividend Yield ETF is more actively traded (748,441 versus 1,927,029). Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Vanguard International High Dividend Yield ETF for 50 Days on average.
| INCY | VYMI | |
|---|---|---|
Market Cap | $22.85B | $22.80B |
Volume | 1,927,029 | 748,441 |
Sector | Health | Broad Market / Factor |
52-Week High | $129.93 | $107.13 |
52-Week Low | $83.80 | $82.92 |
Typical Hold Time | 33 Days | 50 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
VYMI trades at $100.27 with minimal daily movement (+0.04%). Technical indicators show a bearish trend with moving averages signaling caution, though oscillators are neutral. Recent news highlights institutional accumulation and positive performance comparisons to peers. The ETF's international high-dividend strategy focuses on financials, energy, and healthcare sectors.
Outlook remains mixed: bullish sentiment from media and institutional inflows contrasts with bearish technicals. Key opportunities include sector alignment with rising rates and attractive yield; risks involve global economic volatility and concentrated financial exposure. Investors should weigh dividend stability against technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
